Phio Pharmaceuticals Begins Commercial-Scale Production of Lead Drug PH-762
Summary
Phio Pharmaceuticals has begun commercial-scale cGMP production of its lead drug candidate, PH-762, with Nitto Denko Avecia. This critical operational milestone follows the manufacturing agreement announced in March and the recent completion of the Phase 1b clinical trial for PH-762. The new drug supply is essential for advancing PH-762 into its next phase of clinical development, de-risking future trial supply for this key immuno-oncology asset.
At the time of this announcement, PHIO was trading at $1.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.1M. The 52-week trading range was $0.81 to $4.19. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: TMX Newsfile.